Factors Causing False Fasting Insulin Results
The most critical factors causing false fasting insulin results are insulin autoantibodies (which can falsely elevate measured insulin levels), improper sample handling (causing in vitro glycolysis), and cross-reactivity with proinsulin in older immunoassays.
Primary Causes of False Elevation
Insulin Autoantibodies
- Insulin autoimmune syndrome is the most clinically significant cause of falsely elevated fasting insulin 1
- Antibodies interfere with insulin immunoassays, causing dramatically elevated readings (e.g., 194.7 mIU/L) while glucose and C-peptide remain normal 1
- Most commonly reported in Japanese and Korean populations, but occurs in Caucasians 2
- Associated with autoimmune diseases or exposure to sulfhydryl-containing drugs 2
- Detection method: Perform radiobinding assay (RBA) for anti-insulin antibodies and gel filtration chromatography showing insulin complexed with 150 kDa IgG 1
- Can cause actual hypoglycemia in late postprandial period as insulin dissociates from antibodies in unregulated fashion 2
Assay Cross-Reactivity
- Older insulin immunoassays cross-react with proinsulin and 31/32/33 split products 3
- This leads to overestimation of "true" insulin levels
- Modern specific microparticle immunoassays minimize this interference 3
- Different assay platforms yield different results - complementary testing on multiple platforms may be needed 1
Sample Collection and Handling Issues
Pre-analytical Errors
- In vitro glycolysis from delayed sample processing causes artifactual hypoglycemia, making insulin appear inappropriately elevated relative to glucose 4
- Samples must be processed promptly or collected in tubes with glycolysis inhibitors
- Improper sample collection is a major source of artifactual results 4
Interfering Substances
- Various medications and substances can interfere with glucose measurement, indirectly affecting insulin interpretation 5
- Hemolysis can affect some assay methods
Medication-Related Interferences
Proton Pump Inhibitors
- PPIs cause spuriously elevated chromogranin A levels (not insulin directly, but relevant in neuroendocrine tumor workup) 6
- Must discontinue PPIs for at least 1 week before measuring gastrin levels in suspected gastrinoma 6
Exogenous Insulin or Secretagogues
- Factitious hypoglycemia from surreptitious insulin injection shows high insulin with low C-peptide 4, 2
- Sulfonylureas or meglitinides cause high insulin AND high C-peptide 7
- Critical distinction: Measure C-peptide, proinsulin, and screen for oral hypoglycemic agents when insulin is elevated 2
Clinical Context Affecting Interpretation
Renal Insufficiency
- Affects clearance of insulin and C-peptide, potentially elevating measured levels 2
- Diagnostic criteria for hyperinsulinemic hypoglycemia assume absence of renal insufficiency 2
Timing and Physiologic State
- Recurrent hypoglycemia shifts glycemic thresholds for counter-regulatory hormones, making cortisol appear inappropriately low 2
- Post-gastric bypass patients may have nesidioblastosis causing genuine hyperinsulinemia 2
- High hematocrit increases whole blood glucose readings, affecting insulin-to-glucose ratio interpretation 5
Diagnostic Approach to Suspected False Results
When fasting insulin appears inappropriately elevated:
- Verify glucose measurement - ensure proper sample handling, no glycolysis
- Measure C-peptide and proinsulin simultaneously 2
- Screen for sulfonylureas/meglitinides in plasma or urine 7
- Test for insulin antibodies via RBA if insulin markedly elevated with normal C-peptide and glucose 1
- Consider PEG precipitation to measure free insulin separate from antibody-bound insulin 1
- Repeat on different assay platform if results inconsistent with clinical picture 1
Key Pitfalls to Avoid
- Do not interpret isolated insulin elevation without simultaneous glucose, C-peptide, and proinsulin 2
- Do not use insulin/glucose ratios - they have no diagnostic utility 2
- Do not assume elevated insulin means insulinoma without excluding antibodies and exogenous sources 2, 1
- Do not measure insulin during intercurrent illness or on medications affecting insulin sensitivity 2